PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst

Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable Accelerated Approval and set a phase 3 trial design. Strong partnership with Novartis provides financial strength and development support for votoplam for treatment of HD patients, with up to $1.9 billion in milestone payments possible.